Pre-clinically, Mre11 depletion or blockade not only reversed platinum resistance, but we also identified a synthetic lethality approach targeting Mre11 in XRCC1 deficient platinum sensitive ovarian cancers. This evidence concerns the gene XRCC1 and ovarian carcinoma.